Accelerate Diagnostics (MEX:AXDX) Piotroski F-Score: 0 (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:AXDX Accelerate Diagnostics Inc MEX:AXDX
12 GF Score
Price MXN1.75
View Full Analysis

What is Accelerate Diagnostics Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Accelerate Diagnostics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Accelerate Diagnostics's Piotroski F-Score or its related term are showing as below:

Accelerate Diagnostics  (MEX:AXDX) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Accelerate Diagnostics Piotroski F-Score Related Terms


Accelerate Diagnostics Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Accelerate Diagnostics's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accelerate Diagnostics Piotroski F-Score Chart

Accelerate Diagnostics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 2.00 5.00 3.00 3.00

Accelerate Diagnostics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 4.00 4.00 3.00
MEX:AXDX
12GF Score
Accelerate Diagnostics Inc MEX:AXDX
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Net Income was -236.165 + -212.293 + -288.246 + -199.985 = MXN-936.7 Mil.
Cash Flow from Operations was -140.272 + -138.921 + -60.863 + -105.697 = MXN-445.8 Mil.
Revenue was 48.478 + 54.704 + 58.579 + 58.73 = MXN220.5 Mil.
Gross Profit was 11.999 + 12.384 + 16.855 + 9.364 = MXN50.6 Mil.
Average Total Assets from the begining of this year (Dec23)
to the end of this year (Dec24) was
(532.414 + 509.87 + 418.926 + 636.292 + 595.555) / 5 = MXN538.6114 Mil.
Total Assets at the begining of this year (Dec23) was MXN532.4 Mil.
Long-Term Debt & Capital Lease Obligation was MXN1,031.0 Mil.
Total Current Assets was MXN463.8 Mil.
Total Current Liabilities was MXN650.7 Mil.
Net Income was -302.73 + -561.206 + 15.851 + -220.631 = MXN-1,068.7 Mil.

Revenue was 50.686 + 50.077 + 57.465 + 51.381 = MXN209.6 Mil.
Gross Profit was 18.223 + 13.698 + 1.864 + 10.745 = MXN44.5 Mil.
Average Total Assets from the begining of last year (Dec22)
to the end of last year (Dec23) was
(1267.532 + 919.311 + 855.103 + 684.981 + 532.414) / 5 = MXN851.8682 Mil.
Total Assets at the begining of last year (Dec22) was MXN1,267.5 Mil.
Long-Term Debt & Capital Lease Obligation was MXN626.9 Mil.
Total Current Assets was MXN415.3 Mil.
Total Current Liabilities was MXN204.3 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Accelerate Diagnostics's current Net Income (TTM) was -936.7. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Accelerate Diagnostics's current Cash Flow from Operations (TTM) was -445.8. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec23)
=-936.689/532.414
=-1.75932451

ROA (Last Year)=Net Income/Total Assets (Dec22)
=-1068.716/1267.532
=-0.84314716

Accelerate Diagnostics's return on assets of this year was -1.75932451. Accelerate Diagnostics's return on assets of last year was -0.84314716. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Accelerate Diagnostics's current Net Income (TTM) was -936.7. Accelerate Diagnostics's current Cash Flow from Operations (TTM) was -445.8. ==> -445.8 > -936.7 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=1031.043/538.6114
=1.91426138

Gearing (Last Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=626.927/851.8682
=0.73594366

Accelerate Diagnostics's gearing of this year was 1.91426138. Accelerate Diagnostics's gearing of last year was 0.73594366. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec24)=Total Current Assets/Total Current Liabilities
=463.789/650.719
=0.71273315

Current Ratio (Last Year: Dec23)=Total Current Assets/Total Current Liabilities
=415.292/204.268
=2.0330742

Accelerate Diagnostics's current ratio of this year was 0.71273315. Accelerate Diagnostics's current ratio of last year was 2.0330742. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Accelerate Diagnostics's number of shares in issue this year was 25.207. Accelerate Diagnostics's number of shares in issue last year was 14.577. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=50.602/220.491
=0.2294969

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=44.53/209.609
=0.21244317

Accelerate Diagnostics's gross margin of this year was 0.2294969. Accelerate Diagnostics's gross margin of last year was 0.21244317. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec23)
=220.491/532.414
=0.41413449

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec22)
=209.609/1267.532
=0.16536782

Accelerate Diagnostics's asset turnover of this year was 0.41413449. Accelerate Diagnostics's asset turnover of last year was 0.16536782. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+1+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Accelerate Diagnostics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.


Accelerate Diagnostics Business Description

Address 3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714
Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.
12GF Score

Get the complete analysis for MEX:AXDX

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1.75
Price